Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial

Nottingham University Hospital (City Campus), Nottingham, UK
Beatson West of Scotland Cancer Centre, Glasgow, UK
University of Heidelberg, Heidelberg, Germany
Centre Hospitalier et Universitaire (CHU) de Nantes, Nantes, France
University Hospital, Uppsala, Sweden
VU University Medical Center, Amsterdam, the Netherlands
University of Catania Medical School, Catania, Italy
Carlos Haya, Málaga, Spain
Sanofi Oncology, Cambridge, Massachusetts, USA
Genzyme Europe B.V, Naarden, the Netherlands
Genzyme S.A.S, St Germain-en-Laye, France
Institut Paoli-Calmettes, Marseille, France
Vol. 98 No. 2 (2013): February, 2013